• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Ethics in clinical research evolves

06.03.2017/in News /by ValeriiaKirienko

For the first time since it was issued in 1991, the Common Rule – the set of federal regulations for ethical conduct of human-subjects research – has been updated. The Common Rule was amended not only by department initiative but also by more than 2100 public proposals that US Health Department started to accepts back in 2015. An article written by Health Department officials that gives reflection to new amendments was recently published in the New England Journal of Medicine.

Authors note that proposal to improve informed consent so that it would be easier to understand received substantial public support as informed consent forms are growing longer under new regulatory rules. New rule will order to give the information that a “reasonable person” would want to have to make a decision. Patient information leaflet should also be posted online.

Oversight will become more flexible. Research participants could be better protected if less time and effort were devoted to the oversight of low-risk studies. New rule facilitates a possibility for institutional review boards (IRB’s) administrators, and researchers to focus on ensuring appropriate protection in higher-risk studies.

Moreover, researchers will be given a permission to seek consent which allows participants to agree to researchers’ using their identifiable private information or identifiable biospecimens, originally obtained for other purposes in future studies that are not developed yet.

The new rule also adopts the proposal to generally require a single IRB review only for multi-institutional studies conducted in the United States.

Health Department paid attention not only to suggestions to implicate some of useful procedures into practice but also to comments that opposed original department’s proposals. For example, the new rule does not adopt the proposal to cover researchers’ use of unidentified biospecimens (such as leftover portions of blood samples) and to require informed consent for such research. Commenters’ complaints about the complexity of some proposals also shaped the final rule, including the federal agencies’ decision not to adopt the proposal to extend the Common Rule to clinical trials that are not federally funded.

Many of these amendments will come into force in 2018. Government-funded research in the US defines general scientific research direction all over the world, thus showing pharmaceutical industry a way to further business development. Focus on protection of research participants will result in greater trust of community in the research enterprise.

Source: http://www.nejm.org/doi/full/10.1056/NEJMp1700736

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 3 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Pharmacovigilance market grows with implementation of new regulatory requir... Clinical Research and Modern Gadgets
Scroll to top